Absolute Science Blog


2.28.2006

Episode 13: Links

Tosk - Biotech company founded by Patrick Fogarty.

Radioactive Drugs

  • A detailed article about Bexxar and Zevalin, the two radioimmunotherapy drugs that hotly competed for FDA approval and market share. Zevalin was approved first.
  • (Note: Zevalin must be refrigerated, and has a shorter half life than Bexxar. Bexxar has two components that must be mixed: One refrigerated and one frozen until use. See this powerpoint for extensive info on the two drugs.)
  • A nice chart comparing Bexxar and Zevalin.
  • Zevalin seems to sell better than Bexxar. In the first quarter of 2004, Bexxar sales were $1.3 million according to Corixa. Zevalin sales were $16.7 million in the first 9 months of 2005. (Although Zevalin is easier to store, this is probably not the only reason it sells better.)

Personalized Cancer Vaccines

2 Comments:

  • THIS SEGMENT WAS WELL DONE. IT IS GOOD TO SEE HOW A SCIENTIFIC IDEA CAN EVOLVE INTO REAL BUSINESS OPPORTUNITES. IT WOULD BE HELPFUL TO HAVE FURTHER SEGMENTS ON HOW TO DEVLOP A BUSINESS IN THIS SECTOR OF THE MARKET.A COMMENT THAT STANDS OUT FROM THE DISUSSION WAS THAT NONE OF THE GENERAL BUSINESS PLANS REALLY SUITED THE BIOTECH AREA.

    By Anonymous Anonymous, at 9:38 AM  

  • Excellent segment. A critical component to append to such discussions would be a reading list, other websites etc that a listener may access to obtain further or more detailed information. As a standard feature of appearing on your webcast, the speaker would thus be requested to provide a concise list of the most useful "references" to which an interested listener can turn for further information on the topic.

    By Anonymous Anonymous, at 11:20 AM  

Post a Comment

Links to this post:

Create a Link

<< Home